Skip to content
MarketScale
‹ Back to IndustriesHealthcare

CurveBeam Connect: The Future of Syndesmosis Evaluation

On this month’s edition of CurveBeam Connect, Vinti Singh, Director of Marketing at CurveBeam interviews Alexej Barg, M.D., an orthopedic surgeon at the University of Utah. Dr. Barg specializes in the care of the foot and ankle, as well as reconstruction of traumatic injuries to the foot, ankle replacement, and joint preserving procedures. Prior…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CurveBeam AI on MarketScale.

Share

On this month’s edition of CurveBeam Connect, Vinti Singh, Director of Marketing at CurveBeam interviews Alexej Barg, M.D., an orthopedic surgeon at the University of Utah.

Dr. Barg specializes in the care of the foot and ankle, as well as reconstruction of traumatic injuries to the foot, ankle replacement, and joint preserving procedures.

Prior to coming to the University of Utah where Dr. Barg has set up a very impressive biomedical research lab, both in terms of size and the breadth of projects, he was the head of the Orthopedic Department at the University of Basel in Switzerland.

Dr. Barg currently serves as a reviewer for numerous medical journals including Foot & Ankle International, Journal of Biomechanics, Clinical Anatomy, and BMC Musculoskeletal Disorders, and is well published in foot and ankle replacement.

Currently, Dr. Barg is working with a variety of other researchers on a series of weight-bearing CT projects, including two cadaver research studies. On working with Dr. Arne Burssens on a templating method, Dr. Barg said: “we’re able to compare the healthy side versus the injury side and can detect very small differences in imaging using weight-bearing, which we’re not able to do using conventional radiographs and MRI.”

Give this podcast a listen to hear Singh and Dr. Barg break down his recent presentation on evaluating syndesmosis, his discoveries on the effect that torque plays in syndesmosis measurement, and whether this findings could translate to imaging in the clinical setting.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

CurveBeam AI

Part of this channel

CurveBeam AI

AI-powered 3D bone analysis for orthopedic surgical planning.

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512